|Dr. Anil R. Diwan||Exec. Chairman, Pres & Sec.||472.92k||N/A||1959|
|Ms. Meeta R. Vyas SB, MBA||Chief Financial Officer||129.6k||N/A||1959|
|Dr. Eugene Seymour||Chief Exec. Officer Emeritus||1.29M||N/A||1941|
|Dr. Randall W. Barton Ph.D.||Chief Scientific Officer & Chief Regulatory Officer||N/A||N/A||1947|
|Dr. Irach B. Taraporewala||Consultant & Director||N/A||N/A||1956|
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as injectable and oral anti-influenza nanoviricide drug for H7N9, Bird Flu H5N1, other Highly Pathogenic Influenzas, Epidemic Influenzas, and Seasonal Influenzas; DengueCide, an anti-dengue nanoviricide which is in pre-clinical development; and HIVCide, an anti-human immunodeficiency virus drug candidate. It is also developing HerpeCide, a skin cream for the treatment of cold sores and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
NanoViricides, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.